ClinicalTrials.gg
Enrolling by invitationNCT06531967mBoxUpdated Aug 1, 2024

Predicting Mortality in Kidney Transplant Recipients

An observational study in Death, sponsored by Paris Translational Research Center for Organ Transplantation. Enrolling by invitation at 11 sites in 4 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by Paris Translational Research Center for Organ Transplantation · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
13,000
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Death with a site in France — 14 open to participants now, 15 under way, 3 of them phase 3. Death · France.

Planned enrollment
3rd of 37
13,000 · median 354
Started
2004
with 1 other
Observational
38 of 51
10 open now
Primary completion
2024-06
later than 1 of 14 live
Registered
42nd of 51
by date

Among the 51 studies in Death with a site in France, this one is the 3rd largest by planned enrollment of the 37 observational ones that give a count, is one of 2 that started in 2004, is one of 38 observational ones, reaches primary completion later than 1 of the 14 other live ones, and was the 42nd registered.

Death

457 studies on the registry are indexed under Death; 85 are open to participants now.

Browse Death studies →

Open to participants now

14 of the 51 studies in Death with a site in France are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 58 Death studies recruiting now, 43 (74%) set no upper age limit and 8 (14%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Death with a site in France, or all of them as a file.
02

Study summary

Accurately predicting kidney recipient risk of death has a crucial interest because of the organ shortage, the need to optimize allograft allocation by identifying high-risk patients who may not benefit from a transplant and improve the clinical decision-making after transplant to ensure that each patient survives as long as possible.

However, according to a literature review the investigators performed, studies attempting to develop a kidney recipient death prediction model suffer from many shortcomings, including the lack of key risk factors, use of biased registry data, small sample size, lack of external validation in different countries and subpopulations, and short follow-up.

The present study thus aimed to address these limitations and develop a robust, generalizable kidney recipient death prediction model.

Read the detailed description

The number of individuals suffering from end-stage chronic renal disease (ESRD) worldwide has increased over time, exceeding seven million of patients in 2020. For individuals with ESRD, kidney transplantation is the best treatment in terms of patient survival, quality of life and from a cost-effective standpoint, as compared with dialysis, even in comorbid or elderly populations.

Although the number of kidney transplantations performed each year has increased as well, it follows a lower pace than the increase of individuals on the waiting-list, resulting in an organ shortage. There is therefore a need to optimize allograft allocation by identifying the high-risk patients who may not benefit from a transplant and improve the clinical decision-making after transplant to ensure that each patient survives as long as possible.

In this context, a kidney recipient death prediction model may improve transplant clinical practice, allowing for the ability to evaluate the individual risk of post transplant mortality, already before undergoing transplantation, thereby guiding decision making. However, developing such a model is a very difficult task, as death after kidney transplantation depends on many parameters, such as donor age, history or cause of death, imaging parameters, patients' past medical history (e.g. diabetes, dialysis duration, hypertension), patients' biological parameters, as well as the function of the allograft, which depends on patients' immunological factors, or allograft related parameters such as HLA mismatches or cold ischemia time.

The goal of the present study was therefore to identify the determinants of death after kidney transplantation, and to develop and validate a prediction model that would help optimize allograft allocation and post-transplant patient management, using a large, international, highly phenotyped cohort of kidney recipients with extensive data collection and long-term follow-up.

03

Conditions studied

  • Death

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult, de novo, kidney recipients who received only a kidney transplant

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult kidney recipients

Exclusion criteria

Exclusion Criteria:

  • Multi-organ transplantation
  • Prior kidney transplant
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
13,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Necker hospital from Paris, France

    Kidney recipients from Necker hospital

    Other: No intervention

  • Saint-Louis hospital from Paris, France

    Kidney recipients from Saint-Louis hospital

    Other: No intervention

  • Bichat hospital from Paris, France

    Kidney recipients from Bichat hospital

    Other: No intervention

  • Bretonneau hospital from Tours, France

    Kidney recipients from Bretonneau hospital

    Other: No intervention

  • Toulouse hospital, France

    Kidney recipients from Toulouse hospital

    Other: No intervention

  • KU Leuven, Belgium

    Kidney recipients from KU Leuven

    Other: No intervention

  • Liege hospital from Belgium

    Kidney recipients from Liege hospital

    Other: No intervention

  • Leiden University Medical Center from the Netherlands

    Kidney recipients from Leiden University Medical Center

    Other: No intervention

  • Hospital of the University of Pennsylvania from Philadelphia, US

    Kidney recipients from Hospital of the University of Pennsylvania

    Other: No intervention

  • Mayo Clinic from Phoenix, US

    Kidney recipients from Mayo Clinic

    Other: No intervention

  • UCSF database

    Kidney recipients data from real-world UCSF database

    Other: No intervention

  • AP-HP database

    Kidney recipients data from real-world AP-HP database

    Other: No intervention

Interventions

  • OtherNo intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. Patient death

    Patient death

    Time frame: Up to 10 years after kidney transplantation

07

Study locations

11 sites
  • Department of Medicine, Mayo Clinic
    Phoenix, Arizona 85054, United States
  • Bakar Computational Health Sciences Institute, University of California
    San Francisco, California 94158, United States
  • Penn Transplant Institute, Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Department of Nephrology and Renal Transplantation, University Hospitals Leuven
    Leuven, Belgium
  • Division of Nephrology, University Hospital Liège (CHU)
    Liège, Belgium
  • Necker hospital
    Paris, France
  • Saint-Louis hospital
    Paris, France
  • Tenon hospital
    Paris, France
  • Department of Nephrology and Organ Transplantation, Toulouse University Hospital
    Toulouse, France
  • Department of Nephrology and Clinical Immunology, University Hospital of Tours
    Tours, France
  • Leiden Transplant Center, Leiden University Medical Center
    Leiden, Netherlands
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2004 to primary completion in Jun 2024, 245 months.

Of 85 non-industry observational studies under Death, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 245. This study's 245 months is above that.

Counting every sponsor, half of 88 studies reached it within 69 months; a quarter within 23 and three quarters within 245.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Aug 1, 2024
StartActual
Jan 1, 2004
Primary completionActual
Jun 1, 2024
CompletionEst.
Aug 1, 2024
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06531967
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Jan 1, 2004
Primary completion
Jun 1, 2024
Completion
Aug 1, 2024 (estimated)
Last update
Aug 1, 2024

Study contacts

Alexandre Loupy
principal investigator · Paris Institute for Transplantation and Organ Regeneration (PITOR)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion